TRCT
CYT

Tower Research Capital (TRC)’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Tower Research Capital (TRC)’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,049
Closed -$9.27K – 6274
2023
Q4 		$9.27K Sell
3,049
-3,868
-56% -$11.7K ﹤0.01% 4412
2023
Q3 		$19.6K Buy
6,917
+5,211
+305% +$14.4K ﹤0.01% 3393
2023
Q2 		$4.44K Buy
+1,706
New +$3.57K ﹤0.01% 4947
2022
Q4 		– Sell
-5,859
Closed -$11K – 6569
2022
Q3 		$11K Sell
5,859
-141
-2% -$368 ﹤0.01% 4486
2022
Q2 		$18K Buy
6,000
+1,442
+32% +$3.68K ﹤0.01% 3928
2022
Q1 		$17K Buy
4,558
+2,380
+109% +$13.5K ﹤0.01% 3724
2021
Q4 		$25K Buy
2,178
+1,781
+449% +$27.1K ﹤0.01% 3449
2021
Q3 		$7K Buy
+397
New +$7.42K ﹤0.01% 4698

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Tower Research Capital (TRC)'s CYT Position: Q1 2024 in Review

Tower Research Capital (TRC) sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 3,049 shares — an estimated $9.27K sold.

Tower Research Capital (TRC) first reported a position in CYT in Q3 2021 and held it in 8 quarters. The position peaked at $25K in Q4 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Tower Research Capital (TRC) reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,049 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $9.27K.
  • Tower Research Capital (TRC) first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s Cyteir Therapeutics, Inc. Common Stock position peaked at $25K in Q4 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.